Brigatinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 30mg, 90mg, 180mg
Reference Brands: Alunbrig (USA)
Category:
Oncology Cancer Care
Brigatinib is a tyrosine kinase inhibitor (TKI) used in the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC). It works by blocking abnormal ALK protein activity that promotes cancer cell growth. Brigatinib is available as oral film-coated tablets in 30 mg, 90 mg, and 180 mg strengths. It is prescribed as a targeted therapy for patients who have progressed on or are intolerant to other ALK inhibitors like crizotinib.
Brigatinib is available in Tablets
and strengths such as 30mg, 90mg, 180mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Brigatinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Brigatinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing